| Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1374 | 2021 |
| SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... Nature medicine 27 (4), 622-625, 2021 | 1264 | 2021 |
| Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization S Cele, L Jackson, DS Khoury, K Khan, T Moyo-Gwete, H Tegally, JE San, ... Nature 602 (7898), 654-656, 2022 | 1013 | 2022 |
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ... Nature 509 (7498), 55-62, 2014 | 782 | 2014 |
| The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, ... Journal of virology 85 (10), 4828-4840, 2011 | 591 | 2011 |
| T cell responses to SARS-CoV-2 spike cross-recognize Omicron R Keeton, MB Tincho, A Ngomti, R Baguma, N Benede, A Suzuki, K Khan, ... Nature 603 (7901), 488-492, 2022 | 482 | 2022 |
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1 PL Moore, ET Crooks, L Porter, P Zhu, CS Cayanan, H Grise, P Corcoran, ... Journal of virology 80 (5), 2515-2528, 2006 | 420 | 2006 |
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection ES Gray, PL Moore, IA Choge, JM Decker, F Bibollet-Ruche, H Li, ... Journal of virology 81 (12), 6187-6196, 2007 | 416 | 2007 |
| Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape PL Moore, ES Gray, CK Wibmer, JN Bhiman, M Nonyane, DJ Sheward, ... Nature medicine 18 (11), 1688-1692, 2012 | 374 | 2012 |
| SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection S Cele, L Jackson, DS Khoury, K Khan, T Moyo-Gwete, H Tegally, JE San, ... MedRxiv, 2021 | 362 | 2021 |
| Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection PL Moore, N Ranchobe, BE Lambson, ES Gray, E Cave, MR Abrahams, ... PLoS pathogens 5 (9), e1000598, 2009 | 273 | 2009 |
| New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency NA Doria-Rose, JN Bhiman, RS Roark, CA Schramm, J Gorman, ... Journal of virology 90 (1), 76-91, 2016 | 242 | 2016 |
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals GD Tomaras, JM Binley, ES Gray, ET Crooks, K Osawa, PL Moore, ... Journal of virology 85 (21), 11502-11519, 2011 | 239 | 2011 |
| Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes CK Wibmer, JN Bhiman, ES Gray, N Tumba, SS Abdool Karim, ... PLoS pathogens 9 (10), e1003738, 2013 | 225 | 2013 |
| Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies JN Bhiman, C Anthony, NA Doria-Rose, O Karimanzira, CA Schramm, ... Nature medicine 21 (11), 1332-1336, 2015 | 224 | 2015 |
| Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors ES Gray, N Taylor, D Wycuff, PL Moore, GD Tomaras, CK Wibmer, ... Journal of virology 83 (17), 8925-8937, 2009 | 211 | 2009 |
| The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection PL Moore, ES Gray, IA Choge, N Ranchobe, K Mlisana, SS Abdool Karim, ... Journal of virology 82 (4), 1860-1869, 2008 | 202 | 2008 |
| SARS-CoV-2 501Y CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv …, 2021 | 201 | 2021 |
| Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop PL Moore, ES Gray, D Sheward, M Madiga, N Ranchobe, Z Lai, ... Journal of virology 85 (7), 3128-3141, 2011 | 200 | 2011 |
| Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants L Wang, T Zhou, Y Zhang, ES Yang, CA Schramm, W Shi, A Pegu, ... Science 373 (6556), eabh1766, 2021 | 189 | 2021 |
